Search results for "protocols"

showing 10 items of 782 documents

Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers

2006

Background Biliary tract cancers are uncommon tumors with a poor prognosis and most patients present with invasive and inoperable disease at diagnosis. Chemotherapy represents a palliative treatment, with poor response rates and a median survival of less than 6 months. Oxaliplatin and gemcitabine have shown an interesting activity as single agents in this group of patients. Patients and methods We carried out a multicenter phase II study to evaluate the efficacy and safety of combined oxaliplatin and gemcitabine in locally advanced and metastatic biliary tract carcinoma. The schedule of chemotherapy included oxaliplatin 100 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1 and 8, every 21…

MaleOncologymedicine.medical_specialtyOrganoplatinum CompoundsSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPhases of clinical researchAdenocarcinomaNeutropeniaDeoxycytidineDrug Administration ScheduleInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSurvival rateAgedChemotherapybusiness.industryCombination chemotherapyHematologyMiddle Agedmedicine.diseaseGemcitabineGemcitabineOxaliplatinOxaliplatinSurvival RateBile Duct NeoplasmsOncologyBiliary tractFemaleGallbladder Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2010

Anal cancer is strongly associated with human papilloma virus (HPV) infection. Using polymerase chain reaction (PCR), the presence of the HPV genome has been identified in 80%–85% of cases. Other important risk factors include human immunodeficiency virus (HIV), immune suppression in transplant recipients and cigarette smoking. Herpes simplex virus (HSV)may play a secondary role in disease progression.Dietaryhabits, chronic inflammatory diseases and the presence of haemorrhoids do not appear to predispose to epidermoid anal cancer. Previous (gynaecological, lymphoma or leukemia) or subsequent (e.g. lung, bladder, vulva, vagina or breast) malignancy is more likely in anal cancer patients. Th…

MaleOncologymedicine.medical_specialtyPalliative careAnal CarcinomaDiseaseMalignancyGastroenterologyMeta-Analysis as TopicRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineGenetic predispositionHumansAnal cancerNeoplasm InvasivenessNeoplasm MetastasisNeoplasm StagingRandomized Controlled Trials as TopicSalvage TherapyRadiotherapybusiness.industryIncidencePalliative CareHPV infectionCancerHematologyAnus Neoplasmsmedicine.diseaseCombined Modality TherapyEuropeTreatment OutcomeOncologyFemalebusinessFollow-Up StudiesAnnals of Oncology
researchProduct

Italian clinical research in non-small-cell lung cancer

2005

ABSTRACT Lung cancer is the most common cause of cancer deaths in both men and women worldwide and has a poor prognosis. Non-small-cell lung cancer (NSCLC) represents approximately 80% of all lung cancers. Surgery is the only curative treatment of NSCLC but only 15–20% of tumours can be radically resected with a survival of about 40% at 5 years. Considering these disappointing results NSCLC is one of the most frequent subjects of clinical research worldwide. Italy is playing an important role in the clinical research of NSCLC performing phase I, II and III trials, prevalently by cooperative groups, and achieving important results that contributed to define the standard treatment for NSCLC p…

MaleOncologymedicine.medical_specialtyPoor prognosisLung NeoplasmsNSCLCCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerneoplasmsAgedClinical Trials as TopicLungbusiness.industryStandard treatmentCancerHematologymedicine.diseaseItalian clinical researchrespiratory tract diseasesSurvival RateClinical trialTreatment OutcomeClinical researchmedicine.anatomical_structureItalyOncologyChemotherapy AdjuvantFemaleRadiotherapy AdjuvantNon small cellCisplatinLung cancerbusiness
researchProduct

Olfaction in chemotherapy for head and neck malignancies

2015

Abstract Objective Systemic chemotherapy for different malignancies occurs alongside various side effects, including reduced sensory function. To date, little is known about the effect of chemotherapeutic agents on olfaction. The aim of this study was to provide new data about changes in sense of smell during chemotherapy among patients with advanced squamous cell carcinomas of the head and neck region. Methods In a prospective, controlled cohort study of patients undergoing up to three courses of chemotherapy (cis- or carboplatin, 5-fluorouracil and docetaxel), olfaction was evaluated prior to and directly following completing a cycle, as well as 3 weeks later with the beginning of the nex…

MaleOncologymedicine.medical_treatmentDocetaxelSystemic therapyCarboplatinCohort StudiesOlfaction Disorderschemistry.chemical_compound0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsProspective Studies030212 general & internal medicineAged 80 and overSmokingAge FactorsGeneral MedicineMiddle AgedDocetaxelHead and Neck NeoplasmsSensory Thresholds030220 oncology & carcinogenesisCarcinoma Squamous CellFemaleTaxoidsFluorouracilmedicine.drugCohort studyAdultmedicine.medical_specialtyDifferential ThresholdOlfaction03 medical and health sciencesInternal medicinemedicineHumansLaryngeal NeoplasmsAgedCisplatinChemotherapySquamous Cell Carcinoma of Head and Neckbusiness.industryCancerPharyngeal Neoplasmsmedicine.diseaseCarboplatinSurgeryOtorhinolaryngologychemistryControlled Before-After StudiesSurgeryCisplatinbusinessAuris Nasus Larynx
researchProduct

Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas—results of …

2006

Myeloablative radio-chemotherapy with subsequent autologous stem cell transplantation (ASCT) significantly prolongs progression free and probably overall survival in follicular lymphoma (FL) in first remission. The current trial explored prospectively the rate of successful stem cell mobilization in patients with advanced stage FL after initial therapy with either Mitoxantrone, Chlorambucil, Prednisone (MCP) or Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) as part of a prospective randomized comparison of both regimens. ASCT patients received Dexa-BEAM (Dexamethasone, BCNU, Melphalan, Etoposide, Cytarabine) for mobilization of stem cells. Stem cells were collected and a mini…

MaleOncologymedicine.medical_treatmentFollicular lymphomaLymphoma Mantle-CellHematopoietic stem cell transplantationCHOPDexamethasone0302 clinical medicineAutologous stem-cell transplantationGermanyhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesLymphoma FollicularMelphalanEtoposideCytarabineHematopoietic Stem Cell TransplantationHematologyMiddle AgedHematopoietic Stem Cell Mobilization3. Good healthSurvival RateTreatment OutcomeOncologyVincristine030220 oncology & carcinogenesisFemalemedicine.drugAdultmedicine.medical_specialtyVincristinePrednisolone03 medical and health sciencesInternal medicinemedicineHumansCyclophosphamideAgedChemotherapyMitoxantronebusiness.industrymedicine.diseaseCarmustineLeukemia Lymphocytic Chronic B-CellSurgeryDoxorubicinPrednisoneChlorambucilMantle cell lymphomaMitoxantronebusiness030215 immunologyAnnals of Oncology
researchProduct

Condensed Versus Standard Schedule of High-Dose Cytarabine Consolidation Therapy with Pegfilgrastim Growth Factor Support in Acute Myeloid Leukemia

2017

Abstract Background: The concept of intensive post-remission chemotherapy in acute myeloid leukemia (AML) is based on the observation that despite achievement of a first complete remission (CR) after intensive induction therapy virtually all patients relapse in the absence of further treatment. Moreover, randomized studies showed that intensive post-remission consolidation chemotherapy was superior to prolonged low-dose maintenance therapy in younger patients. With regard to consolidation therapy, the landmark study conducted by the Cancer and Leukemia Group B established the current standard for patients aged 60 years and younger with high-dose cytarabine (HDAC) 3g/m² bidaily on days days …

MaleOncologymedicine.medical_treatmentHematopoietic stem cell transplantationGastroenterologyBiochemistryPolyethylene Glycols0302 clinical medicineMaintenance therapyAntineoplastic Combined Chemotherapy ProtocolsMedicineCytarabineMyeloid leukemiaHematologyMiddle AgedChemotherapy regimen3. Good healthSurvival RateLeukemia Myeloid AcuteLeukemiaOncology030220 oncology & carcinogenesisOriginal ArticleFemalePegfilgrastimmedicine.drugAdultmedicine.medical_specialtyAdolescentFilgrastimImmunologyPlatelet TransfusionFilgrastimDisease-Free Survival03 medical and health sciencesInternal medicineHumansIdarubicinSurvival rateChemotherapybusiness.industryDaunorubicinConsolidation ChemotherapyCell BiologyLength of Staymedicine.diseaseSurgeryConsolidation ChemotherapyTransplantationPlatelet transfusionCytarabinebusiness030215 immunologyBlood
researchProduct

Recognition of Neisseria meningitidis by the long pentraxin PTX3 and its role as an endogenous adjuvant.

2015

Long pentraxin 3 (PTX3) is a non-redundant component of the humoral arm of innate immunity. The present study was designed to investigate the interaction of PTX3 with Neisseria meningitidis. PTX3 bound acapsular meningococcus, Neisseria-derived outer membrane vesicles (OMV) and 3 selected meningococcal antigens (GNA0667, GNA1030 and GNA2091). PTX3-recognized microbial moieties are conserved structures which fulfil essential microbial functions. Ptx3-deficient mice had a lower antibody response in vaccination protocols with OMV and co-administration of PTX3 increased the antibody response, particularly in Ptx3-deficient mice. Administration of PTX3 reduced the bacterial load in infant rats c…

MaleOvalbuminGene Expressionlcsh:MedicineMeningococcal VaccinesMeningococcal vaccineMeningitis MeningococcalNeisseria meningitidismedicine.disease_causeMicrobiologyMice03 medical and health sciencesImmune systemAdjuvants ImmunologicAntigenImmunitymedicineAnimalsRats Wistarlcsh:Science030304 developmental biologyMice KnockoutAntigens Bacterial0303 health sciencesNeisseria meningitidis PTX3 vaccination protocolsMultidisciplinarybiology030306 microbiologyNeisseria meningitidisVaccinationlcsh:RPTX3Antibodies BacterialVirologyBacterial LoadImmunity InnateImmunity HumoralRats3. Good healthSerum Amyloid P-ComponentC-Reactive ProteinAnimals Newbornbiology.proteinFemalelcsh:QAntibodyBacterial outer membraneResearch ArticlePLoS ONE
researchProduct

The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen.

2010

OBJECTIVES: To determine the efficacy and safety of different opioids used in doses proportional to the basal opioid regimen for the management of breakthrough pain (BP). METHODS: In 66 patients consecutive patients admitted to a pain relief and palliative care unit, the efficacy and safety of different opioids used in doses proportional to the basal opioid regimen for the management of breakthrough pain (BP) were assessed. The choice of the opioid to be administered as rescue medication was based on the characteristics of patients, clinical stability, compliance, preference, and so on. For each episode, nurses were instructed to routinely collect changes in pain intensity and emerging prob…

MalePalliative careBreakthrough PainAdministration OralPainDrug Administration ScheduleSex FactorsClinical ProtocolsMedicinebreakthrough pain; acute palliative care unit; opioidsHumansAgedPain MeasurementAnalgesicsDose-Response Relationship Drugbusiness.industryPalliative CareAge FactorsopioidsMiddle Agedacute palliative care unitbreakthrough painClinical trialAnalgesics OpioidRegimenAnesthesiology and Pain MedicineNociceptionTreatment OutcomeBasal (medicine)OpioidAnesthesiaFemaleNeurology (clinical)businessCancer painmedicine.drug
researchProduct

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients

2015

// Bruno Vincenzi 1 , Chiara Cremolini 2 , Andrea Sartore-Bianchi 3 , Antonio Russo 4 , Francesco Mannavola 5 , Giuseppe Perrone 6 , Francesco Pantano 1 , Fotios Loupakis 2 , Daniele Rossini 2 , Elena Ongaro 7 , Erica Bonazzina 3 , Emanuela Dell’Aquila 1 , Marco Imperatori 1 , Alice Zoccoli 1 , Giuseppe Bronte 4 , Giovanna De Maglio 7 , Gabriella Fontanini 8 , Clara Natoli 9 , Alfredo Falcone 2 , Daniele Santini 1 , Andrea Onetti-Muda 6 , Salvatore Siena 3 , Giuseppe Tonini 1 and Giuseppe Aprile 7 1 Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy 2 Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy 3 Niguarda Cancer Center, Osped…

MalePathologyColorectal cancerSettore MED/06 - Oncologia MedicaColorectal NeoplasmRetrospective StudieAntineoplastic Combined Chemotherapy ProtocolsTumor Cells Culturededucation.field_of_studyUnivariate analysisBevacizumab; Colorectal cancer; K-Ras; Mutation rate; Prognosis; OncologyLiver NeoplasmsMiddle AgedPrognosisBevacizumabSurvival RateOncologyLiver NeoplasmCohortFemaleK-Ras; mutation rate; colorectal cancer; bevacizumab; prognosisColorectal NeoplasmsK-RasResearch Papermedicine.drugHumanmedicine.medical_specialtyBevacizumabPrognosiMutation ratePopulationBevacizumab; Colorectal cancer; K-Ras; Mutation rate; Prognosis; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins p21(ras); Real-Time Polymerase Chain Reaction; Retrospective Studies; Survival Rate; Tumor Cells Cultured; OncologyReal-Time Polymerase Chain ReactionFollow-Up StudieProto-Oncogene Proteins p21(ras)Internal medicinemedicineHumanseducationSurvival rateRetrospective StudiesNeoplasm StagingAntineoplastic Combined Chemotherapy Protocolbusiness.industryCancerRetrospective cohort studymedicine.diseaseColorectal cancerK-RaMutationbusinessFollow-Up Studies
researchProduct

On the threshold of effective well infant nursery hearing screening in Western Sicily.

2012

Abstract Objective To determine the feasibility and effectiveness of well-infant nursery hearing screening programme for the early identification of hearing impairment, based on transient evoked otoacoustic emission (TEOAE) with a high “screen sensitivity” reducing the number of more expensive secondary level exams. Methods The newborns were screened by non-specialist health workers in well babies nursery at the twentieth day of life for 6 years consecutive. Based on PASS/FAIL criteria and presence/absence of audiological risk factors the newborns were divided into four groups each one with its personal step programme: G1 – PASS without risk factor, free to go home; G2 – PASS with risk fact…

MalePediatricsmedicine.medical_specialtyReferralHearing lossOtoacoustic Emissions SpontaneousOtoacoustic emissionAudiologyHearing screeningScreening programmeCohort StudiesNeonatal ScreeningClinical ProtocolsPredictive Value of TestsRisk FactorsWell-infant nurseryMedicineHumansRisk factorHearing LossSicilybusiness.industryIncidence (epidemiology)Infant NewbornInfantGeneral Medicinemedicine.diseaseSettore MED/32 - AudiologiaAudiometry Evoked ResponseNeonatal screening; Well-infant nursery; Sensorineural hearing loss; Otoacoustic emission;Settore MED/31 - OtorinolaringoiatriaOtorhinolaryngologySensorineural hearing loPediatrics Perinatology and Child HealthFeasibility StudiesOtoacoustic emissionSensorineural hearing lossFemalemedicine.symptombusinessInternational journal of pediatric otorhinolaryngology
researchProduct